CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Life Technologies’ Oncomine Next-Gen Sequencing Power Tools is an analytics offering that will allow cancer researchers to explore results from in-depth analysis of next-generation sequencing (NGS) data, including data from The Cancer Genome Atlas. In total, more than 4,500 paired tumor and samples have been analyzed.
Oncomine NGS Power Tools constitute a suite of software tools that enable cancer researchers to easily survey novel predicted driver mutations and gene fusions across all cancers and within two dozen specific cancer types, as well as explore simple summary analyses that integrate multiple types of gene and pathway aberrations with clinical data.
NGS Power Tools also provide a foundation for specialized biomarker services to pharma and biotech customers to evaluate NGS data for biomarker and companion diagnostic development.
With collaborators from the University of Michigan Medical School, Life Tech scientists used the NGS Power Tools to discover FGFR gene fusions across a range of cancer types.
The investigators discovered FGFR fusions across a highly diverse set of nine distinct tumor types, including lung squamous cell cancer, bladder cancer, thyroid cancer, oral cancer, glioblastoma, and head and neck squamous cell cancer. Normal cell lines transfected with fusion constructs exhibited enhanced growth that was sensitive to FGFR inhibitors, indicating that the fusion genes were acting to drive the cancers.
The Oncomine offering extends the Power Tools product line, which includes Oncomine mutation browser, copy number browser, and gene-expression browser, all of which contain data from sequencing and microarray studies that pharmaceutical companies have used in their drug discovery and development work.
The Oncomine product line was initially developed by Compendia Bioscience, which was acquired by Life Technologies in October 2012.
Life Technologies, 800-955-6288